Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1995 Oct;79(10):874–877. doi: 10.1136/bjo.79.10.874

Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease.

H Mietz 1, K Heimann 1
PMCID: PMC505285  PMID: 7488572

Abstract

AIMS--This study aimed to evaluate both the mean time intervals between retinal disease and the development of proliferative vitreoretinopathy (PVR) and the time intervals at which recurrent PVR develops following various kinds of vitreoretinal disease and surgery. METHODS--One hundred and thirty six consecutive cases of PVR that were seen and operated on between 1991 and 1994 were evaluated retrospectively. Intervals between onset of disease and PVR or recurrent PVR were noted. Conditions leading to PVR, surgical procedures, and the final anatomical and functional results were evaluated. RESULTS--Before PVR was noted for the first time, an average of 1.06 vitreoretinal surgical procedures were performed (range 0 to 3). A mean of 1.99 surgeries were performed to control PVR or to reach an end stage where further surgery would have been unreasonable (range 0 to 5). The average (median) time interval between the onset of the retinal disease and PVR was 2.0 months (range 0.5 to 45 months). The median time intervals between surgery and recurrence for the second, third, or fourth times was also 2.0 months (range 0.5 to 34 months). CONCLUSIONS--PVR starts earliest at 2 weeks after an event and subsequently quietens down within a maximum of 45 months after treatment (median 2 months). PVR may recur more than once but the time course of the disease is likely to be the same for each recurrence.

Full text

PDF
874

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaberg T. M. Management of anterior and posterior proliferative vitreoretinopathy. XLV. Edward Jackson memorial lecture. Am J Ophthalmol. 1988 Nov 15;106(5):519–532. doi: 10.1016/0002-9394(88)90580-6. [DOI] [PubMed] [Google Scholar]
  2. Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor. Graefes Arch Clin Exp Ophthalmol. 1988;226(3):201–205. doi: 10.1007/BF02181181. [DOI] [PubMed] [Google Scholar]
  3. Glaser B. M., Vidaurri-Leal J., Michels R. G., Campochiaro P. A. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. 1993 Apr;100(4):466–470. doi: 10.1016/s0161-6420(93)31620-9. [DOI] [PubMed] [Google Scholar]
  4. Heidenkummer H. P., Kampik A. Vergleichende immunhistochemische Untersuchungen epiretinaler Membranen bei proliferativen vitreoretinalen Erkrankungen. Fortschr Ophthalmol. 1991;88(3):219–224. [PubMed] [Google Scholar]
  5. Hiscott P. S., Grierson I., McLeod D. Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study. Br J Ophthalmol. 1984 Oct;68(10):708–715. doi: 10.1136/bjo.68.10.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lewis H., Aaberg T. M. Anterior proliferative vitreoretinopathy. Am J Ophthalmol. 1988 Mar 15;105(3):277–284. doi: 10.1016/0002-9394(88)90010-4. [DOI] [PubMed] [Google Scholar]
  7. Lopez P. F., Grossniklaus H. E., Aaberg T. M., Sternberg P., Jr, Capone A., Jr, Lambert H. M. Pathogenetic mechanisms in anterior proliferative vitreoretinopathy. Am J Ophthalmol. 1992 Sep 15;114(3):257–279. doi: 10.1016/s0002-9394(14)71790-8. [DOI] [PubMed] [Google Scholar]
  8. Machemer R. Massive periretinal proliferation: a logical approach to therapy. Trans Am Ophthalmol Soc. 1977;75:556–586. [PMC free article] [PubMed] [Google Scholar]
  9. Mietz H., Konen W., Heimann K. Visual outcome of secondary lens implantation after trauma or complicated retinal detachment surgery. Retina. 1994;14(3):212–218. doi: 10.1097/00006982-199414030-00005. [DOI] [PubMed] [Google Scholar]
  10. Ryan S. J. Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 1993 Jan;115(1):1–20. doi: 10.1016/s0002-9394(14)73518-4. [DOI] [PubMed] [Google Scholar]
  11. Smiddy W. E., Maguire A. M., Green W. R., Michels R. G., de la Cruz Z., Enger C., Jaeger M., Rice T. A. Idiopathic epiretinal membranes. Ultrastructural characteristics and clinicopathologic correlation. Ophthalmology. 1989 Jun;96(6):811–821. doi: 10.1016/s0161-6420(89)32811-9. [DOI] [PubMed] [Google Scholar]
  12. Weller M., Heimann K., Wiedemann P. Immunochemical studies of epiretinal membranes using APAAP complexes: evidence for macrophage involvement in traumatic proliferative vitreoretinopathy. Int Ophthalmol. 1988 Jan;11(3):181–186. doi: 10.1007/BF00130621. [DOI] [PubMed] [Google Scholar]
  13. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992 Mar-Apr;36(5):373–384. doi: 10.1016/0039-6257(92)90115-a. [DOI] [PubMed] [Google Scholar]
  14. Wiedemann P., Leinung C., Hilgers R. D., Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229(2):150–152. doi: 10.1007/BF00170548. [DOI] [PubMed] [Google Scholar]
  15. Yeo J. H., Sadeghi J., Campochiaro P. A., Green W. R., Glaser B. M. Intravitreous fibronectin and platelet-derived growth factor. New model for traction retinal detachment. Arch Ophthalmol. 1986 Mar;104(3):417–421. doi: 10.1001/archopht.1986.01050150119041. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES